白皮书
IQVIA Pharma Deals: Half-year review of 2022
2022年9月27日
通过提交此表格,您同意我们的使用条款and隐私政策。您提供的信息可能会收集并自动存储在我们的数据库中,可用于向您发送有关IQVIA和我们的服务的其他信息。此类信息也可以转移到其他国家 /地区的IQVIA公司。版权所有©2018-2022 IQVIA Holdings Inc.及其分支机构。版权所有。

Deal activity in the life sciences sector in H1 2022 was unable to match the pandemic-boosted level seen in H1 2021 as challenging market and economic conditions deterred companies from pursuing certain types of transactions. After rebounding in H1 2021 following the hiatus brought about by the emergence of COVID-19, M&A activity dropped off significantly in H1 2022 both in terms of deal volume and value as the life sciences sector declined in value and caution prevailed among potential purchasers amid much economic and geopolitical uncertainty.

Related solutions